Adams E F, Bhuttacharji S C, Halliwell C L, Loizou M, Birch G, Mashiter K
Clin Endocrinol (Oxf). 1984 Dec;21(6):709-18. doi: 10.1111/j.1365-2265.1984.tb01413.x.
Human pancreatic growth hormone releasing factors (hpGRF(1-40) and hpGRF(1-44) significantly stimulated GH secretion when added to cell cultures of human somatotrophic pituitary tumours for 2 h. There was little difference in potency between the two peptides, and the response of different tumours varied, ranging from 30% to 500% increases in GH secretion over control levels. This stimulatory effect was blocked by somatostatin (SRIF) and bromocriptine. The suppressive effect of bromocriptine, but not of SRIF, was overcome by high doses of hpGRF(1-44). TRH stimulated GH secretion by one of three somatotrophic tumours in cell culture, and it was found to potentiate the stimulatory effects of hpGRF(1-44). These results demonstrate that hpGRFs increase serum GH levels in man by a direct action at the pituitary somatotroph level.
人胰腺生长激素释放因子(hpGRF(1 - 40)和hpGRF(1 - 44))添加到人促生长垂体肿瘤细胞培养物中2小时后,能显著刺激生长激素(GH)分泌。这两种肽的效力差异不大,不同肿瘤的反应有所不同,GH分泌量比对照水平增加30%至500%。这种刺激作用被生长抑素(SRIF)和溴隐亭阻断。高剂量的hpGRF(1 - 44)可克服溴隐亭的抑制作用,但不能克服SRIF的抑制作用。促甲状腺激素释放激素(TRH)在细胞培养中刺激了三分之一的促生长肿瘤分泌GH,并且发现它能增强hpGRF(1 - 44)的刺激作用。这些结果表明,hpGRF通过直接作用于垂体生长激素细胞水平来提高人体血清GH水平。